ICHNOS Sciences is an independent, fully integrated, global U.S.-based biotech company focused on innovation.
“Ichnos Sciences - takes its name from an ancient Greek ????? - /’ík-nos/, which means “footprint” and is dedicated to transforming how people think about and treat cancer, autoimmune deceases and pain, and to leaving an imprint on the lives of those affected by disease,” Dr. Alessandro Riva, MD, CEO of Ichnos Sciences and former Gilead executive said.
The company takes a holistic, disease-centric approach to research, has been structured to work faster, smarter and more collaboratively to accelerate development and quickly bring new treatments to patients.
Our Swiss operation encompasses two biological R&D Centers and a GMP manufacturing facility and focuses on the discovery and development of novel biological entities and drugs comprising monoclonal antibodies and proprietary bispecific format in the field of immune-oncology and autoimmune diseases.
Overall we currently have three assets in the clinic in various stages of development from Phase 1 to Phase 2b. We also have multiple discovery programs based on our proprietary technology platform, BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor). Our molecules and drugs under developments target treatment among others of HER2 positive cancers, multiple myeloma and other malignancies of hematopoietic origin, as well as a variety of solid tumors.
We are looking for highly motivated people who thrive on being challenged and working in an agile, collaborative and multicultural environment to join our multidisciplinary discovery team and play a key role in conducting rigorous, cutting-edge science.